Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event is scheduled to take place from October 15-17, 2024.
Thomas Zindrick, President, CEO, and Chairman of the Board of Genelux, will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim. The discussion is set for October 15, 2024, at 2:00 pm E.T.
During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This presentation offers an opportunity for investors and interested parties to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.
Genelux (NASDAQ: GNLX), un'azienda di immuno-oncologia in fase clinica avanzata, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. L'evento si terrà dal 15 al 17 ottobre 2024.
Thomas Zindrick, Presidente, CEO e Presidente del Consiglio di Amministrazione di Genelux, parteciperà a una conversazione informale con Jason McCarthy, Ph.D., Direttore Generale Senior e Responsabile della Ricerca Biotecnologica di Maxim. La discussione è programmata per il 15 ottobre 2024, alle 14:00 E.T.
Durante la conversazione, Zindrick fornirà approfondimenti sui programmi in fase clinica di Genelux, sui recenti annunci e sui traguardi futuri. Questa presentazione offre un'opportunità per gli investitori e le parti interessate di ottenere informazioni preziose sui progressi e sui piani futuri di Genelux nel campo dell'immuno-oncologia.
Genelux (NASDAQ: GNLX), una compañía de inmuno-oncología en etapa clínica avanzada, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. El evento está programado para llevarse a cabo del 15 al 17 de octubre de 2024.
Thomas Zindrick, Presidente, CEO y Presidente de la Junta de Genelux, participará en una charla informal con Jason McCarthy, Ph.D., Director General Senior y Jefe de Investigación en Biotecnología en Maxim. La discusión está programada para el 15 de octubre de 2024, a las 2:00 p.m. E.T.
Durante la charla, Zindrick proporcionará información sobre los programas en etapa clínica de Genelux, los anuncios recientes y los logros futuros. Esta presentación ofrece una oportunidad para que los inversores y otras partes interesadas obtengan información valiosa sobre el progreso y los planes futuros de Genelux en el campo de la inmuno-oncología.
Genelux (NASDAQ: GNLX), 최후기 임상 단계에 있는 면역종양학 회사가 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. 이 행사는 2024년 10월 15일부터 17일까지 개최될 예정입니다.
Thomas Zindrick Genelux의 회장, CEO 및 이사회 의장이 Jason McCarthy, Ph.D. Maxim의 생명공학 연구 책임자와의 대화에 참여할 것입니다. 이 논의는 2024년 10월 15일 오후 2시 E.T.에 예정되어 있습니다.
대화 중 Zindrick은 Genelux의 임상 단계 프로그램, 최근 발표, 및 향후 이정표에 대한 통찰력을 제공할 것입니다. 이 발표는 투자자들과 관심 있는 당사자들에게 Genelux의 발전과 면역종양학 분야의 미래 계획에 대한 귀중한 정보를 얻을 수 있는 기회를 제공합니다.
Genelux (NASDAQ: GNLX), une entreprise d'immuno-oncologie en phase clinique avancée, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. L'événement est prévu du 15 au 17 octobre 2024.
Thomas Zindrick, Président, CEO et Président du Conseil d'Administration de Genelux, participera à une discussion informelle avec Jason McCarthy, Ph.D., Directeur Général Senior et Responsable de la Recherche en Biotechnologie chez Maxim. La discussion est prévue pour le 15 octobre 2024, à 14h00 E.T.
Au cours de cette discussion, Zindrick fournira des informations sur les programmes cliniques de Genelux, les annonces récentes et les objectifs futurs. Cette présentation offre une opportunité aux investisseurs et aux parties intéressées d'obtenir des informations précieuses sur les progrès et les plans futurs de Genelux dans le domaine de l'immuno-oncologie.
Genelux (NASDAQ: GNLX), ein Unternehmen der Immunonkologie in der späten klinischen Phase, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit angekündigt. Die Veranstaltung findet vom 15. bis 17. Oktober 2024 statt.
Thomas Zindrick, Präsident, CEO und Vorsitzender des Vorstands von Genelux, wird an einem informellen Gespräch mit Jason McCarthy, Ph.D., Senior Managing Director und Leiter der Biotechnologieforschung bei Maxim, teilnehmen. Das Gespräch ist für den 15. Oktober 2024 um 14:00 Uhr E.T. angesetzt.
Während des Gesprächs wird Zindrick Einblicke in Genelux' klinische Programme, aktuelle Ankündigungen und zukünftige Meilensteine geben. Diese Präsentation bietet eine Gelegenheit für Investoren und interessierte Parteien, wertvolle Informationen über den Fortschritt und die zukünftigen Pläne von Genelux im Bereich der Immunonkologie zu erhalten.
- None.
- None.
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place October 15-17, 2024.
Mr. Zindrick will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research, which is scheduled for 2:00 pm E.T. on October 15, 2024.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (GNLX) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Genelux (GNLX) at the 2024 Maxim Healthcare Virtual Summit?
What topics will Genelux (GNLX) discuss during the 2024 Maxim Healthcare Virtual Summit?
Who will be interviewing the Genelux (GNLX) representative at the 2024 Maxim Healthcare Virtual Summit?
